Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NewBiotics, Theratechnologies deal

TH's majority owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), will acquire cancer company NewBiotics. NewBiotics shareholders

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE